Epoetin beta

Red

Brand Name(s):NeoRecormon

Indication:Renal anaemia or anaemia associated with chemotherapy

Rationale:1,2,4,8

Considered:Sep-07

Review Date:Jun-20

Comments:
Drug Safety Update
Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded. Further information at:https://www.gov.uk/drug-safety-update/epoetin-beta-neorecormon-increased-risk-of-retinopathy-in-preterm-infants-cannot-be-excluded
May 2015
…………………………
NICE TA323

1.1 Erythropoiesis stimulating agents (epoetin alfa, beta, theta and zeta, and darbepoetin alfa) are recommended, within their marketing authorisations, as options for treating anaemia in people with cancer who are having chemotherapy.

1.2 If different erythropoiesis stimulating agents are equally suitable, the product with the lowest acquisition cost for the course of treatment should be used.

http://www.nice.org.uk/guidance/ta323/chapter/1-guidance

November 2014